← Leaderboards
Matthew Bernard Wiener
Pharmatech, Inc.
$1,769,329
Attributed
$1,769,329
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $925.3K · FY2010–13$1M$750K$500K$250K$0
'10
'11
'12
'13
Funding mix
By agency
NIH$1,769,329 · 2
By mechanism
R44$1,614,622 · 1
R43$154,707 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignInnovationCommercializationData QualityGap JunctionsGenerationsClinicClinical TrialsConsultCostEnrollmentFundingAmericanBaseAmerican Cancer SocietyCare SystemsAccelerationClinical ResearchAnticancer ResearchCancer CareAntineoplastic AgentsCancer PatientDiagnosisInvestigational Therapies
Grant awards (3)
A Patient Centered Approach to Enrolling Rare Cancer Patients in Clinical Trials$925,328
R44 · FY2013 · CA · contact PI
A Patient Centered Approach to Enrolling Rare Cancer Patients in Clinical Trials$689,294
R44 · FY2012 · CA · contact PI
A Patient-Centered Approach to Enrolling Rare Cancer Patients in Clinical Trials$154,707
R43 · FY2010 · CA · contact PI